Clinical trial · Observational
Predictors of HCC in Post-HCV Cirrhotic Patients After SVR
Study of Clinical and Laboratory Predictors of Hepatocellular Carcinoma in Post-HCV Cirrhotic Patients After Sustained Virologic Response.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to identify clinical and laboratory factors that predict the occurrence of hepatocellular carcinoma (HCC) in Egyptian cirrhotic patients after achieving a sustained virologic response (SVR) to hepatitis C virus (HCV) treatment. This is a retrospective, two-center, case-control study that will include 132 cases and 264 controls. Variables to be analyzed include demographics, liver disease status, metabolic comorbidities, lifestyle factors, medications, as well as laboratory parameters and non-invasive scoring systems.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC - Hepatocellular Carcinoma | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Cases
- description
- SVR patients who developed HCC
- label
- Controls
- description
- SVR patients who did not develop HCC
Primary outcomes (1)
- measure
- occurrence of hepatocellular carcinoma (HCC)
- timeFrame
- from SVR12 achievement to 6-9 years later (time of data collection)
- description
- measure occurrence of HCC in post-HCV liver cirrhosis after achieving SVR, by comparing cases to controls
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * for cases: 1. age ≥ 18 y; 2. HCV related cirrhosis; 3. SVR12 after DAA; 4. radiologic or histologic HCC diagnosis ≤30 Jun 2025 * for controls: As above plus, ≥36 months post SVR without HCC Exclusion Criteria: * for cases: 1. non HCV cirrhosis or combined HCV-HBV cirrhosis; 2. HCC \<6 months before SVR; 3. concomitant cholangiocarcinoma * for controls: Same as cases, plus, loss to follow up before 36 months
References
Publications (0)
Data not yet available